Role of baseline echocardiography prior to initiation of anthracycline-based chemotherapy in breast cancer patients

BMC Cancer

Table 1 Demographics and tumor characteristics

Variables	Groups	N	Percentages
Stage	1	47	21.4
	2	102	46.4
	3	57	25.9
	Not available	14	6.3
Grade	1	29	13.2
	2	80	36.4
	3	98	44.5
	Not available	13	5.9
Laterality	Right side	110	50
	Left side	109	49.5
	Bilateral	1	0.5
T	1	74	33.6
	2	97	44.1
	3	37	16.8
	Not available	12	5.5
N	0	92	41.8
	1	82	37.3
	2	23	10.4
	3	18	8.2
	Not available	5	2.3
M	0	220	100
^aER	Negative	60	27.3
	Positive	158	71.8
	Not available	2	0.9
^bPR	Negative	78	35.5
	Positive	140	63.6
	Not available	2	0.9
^cHER-2	Negative	118	53.6
	Equivocal	67	30.5
	Overexpressed	52	23.6
	Not available	3	1.36
Previous hormone therapy (PHT)	No PHT	131	59.6
	Has had PHT	43	19.5
	Not available	46	20.9
Menopausal status	Premenopausal	90	40.9
	Postmenopausal	109	49.5
	Not available	21	9.6

^aER: Estrogen Receptor Status. ^bPR: Progesterone Receptor Status. ^cHER2: HER-2 Receptor Status.